Loading
Biond Biologics is an Israeli company making antibodies that release new immune brakes so the immune system can attack tumours. Its lead antibody, BND-22, is in a phase 2 study with standard immunotherapy, and BND-35 has finished an early safety study.
Biond Biologics Ltd., at Misgav Industrial Park, Israel, is a private, clinical-stage company developing first-in-class immunotherapies for cancer and immune-mediated diseases. BND-22 is an anti-ILT2 (LILRB1) checkpoint antibody, earlier partnered with Sanofi as SAR444881; Biond announced in March 2025 that it would regain full rights and in August 2025 started a phase 2 study with anti-PD-1 therapy. BND-67 is a first-in-class antibody that targets CD28 shedding and is in a phase 1 study. BND-35 is an anti-ILT3 (LILRB4) antibody aimed at suppressive myeloid cells; first patient dosing in its phase 1 study (NCT06274437) was announced in June 2024, and in October 2024 Biond agreed a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, to test BND-35 with cetuximab. The company website says the BND-35 monotherapy study is completed, while the ClinicalTrials.gov record lists it as terminated. In June 2026 it announced the closing of an USD 8 million investment and collaboration with the Guangzhou-Israel Biotechnology Fund. Its first registered cancer trial as lead sponsor, NCT06274437, was posted on ClinicalTrials.gov in February 2024.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Strategic investment · Investment and collaboration with the Guangzhou-Israel Biotechnology Fund (GIBF); amount from the release title on the company press page. | 2026 | $8M | biondbio.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares CD28, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/